So blame investors for buying in 2015 and forward . Someone owns every share after a legitimate sale.
“To not expect since 2015 DiLUTION, is yet another underscorement of lack of understanding of the investment process Emerging Biotechs have undergone for 3 decades along with regulatory procedures especially with biased FDA. “